Quadrant Capital Group LLC Atreca, Inc. Transaction History

Quadrant Capital Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$1.56 - $3.25 $7,898 - $16,454	-5,063 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$1.61 - $5.2 $8,151 - $26,327	5,063 New	5,063 $16,000
Q4 2021 Feb 01, 2022	SELL	$2.87 - $6.29 $249 - $547	-87 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.91 - $9.07 $427 - $789	87 New	87 $1,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.